INSP Stock Analysis: Inspire Medical Systems | NYSE
Medical Devices | NYSE, USA | Market Cap: 1.353m USD | 12M Return: -62.8% | Charts, Fundamentals & Technical Analysis
Avg Turnover: 44.6M
Qual. Beats: 16
Rev. Trend: 97.6%
Qual. Beats: 3
Warnings
Tailwinds
No distinct edge detected
Seasonality 8.1 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
Inspire Medical Systems, Inc. (NYSE: INSP) is a medical technology company that develops and commercializes minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and select international markets. Its flagship offering, the Inspire system, is an implantable neurostimulation device that continuously monitors a patients breathing and delivers mild stimulation to the hypoglossal nerve to keep the airway open during sleep, serving patients with moderate to severe OSA. The company was incorporated in 2007, is headquartered in Golden Valley, Minnesota, and operates within the medical device industry as a direct-to-physician and direct-to-patient business model targeting an underserved OSA population that struggles with traditional first-line therapies such as continuous positive airway pressure (CPAP).
- GLP-1 weight loss drugs could shrink OSA patient pool
- U.S. Inspire procedure volume drives revenue growth
- Medicare and private insurer reimbursement coverage expands
| Net Income: 131.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.11 > 0.02 and ΔFCF/TA -0.18 > 1.0 |
| NWC/Revenue: 52.16% < 20% (prev 60.49%; Δ -8.33% < -1%) |
| CFO/TA 0.15 > 3% & CFO 136.5m > Net Income 131.1m |
| Net Debt (-254.3m) to EBITDA (80.1m): -3.17 < 3 |
| Current Ratio: 6.34 > 1.5 & < 3 |
| Outstanding Shares: last quarter (28.7m) vs 12m ago -5.31% < -2% |
| Gross Margin: 85.78% > 18% (prev 84.65%; Δ 1.12% > 0.5%) |
| Asset Turnover: 111.5% > 50% (prev 115.0%; Δ -3.49% > 0%) |
| Interest Coverage Ratio: 467.7 > 6 (EBIT TTM 64.1m / Interest Expense TTM 137k) |
| A: 0.52 (Total Current Assets 566.8m - Total Current Liabilities 89.4m) / Total Assets 911.4m |
| B: -0.17 (Retained Earnings -157.8m / Total Assets 911.4m) |
| C: 0.08 (EBIT TTM 64.1m / Avg Total Assets 821.1m) |
| D: 6.66 (Book Value of Equity 792.3m / Total Liabilities 119.0m) |
| Altman-Z'' = 10.39 = AAA |
| DSRI: 1.04 (Receivables 105.1m/92.6m, Revenue 915.2m/840.1m) |
| GMI: 0.99 (GM 84.65% / 85.78%) |
| AQI: 3.11 (AQ_t 0.24 / AQ_t-1 0.08) |
| SGI: 1.09 (Revenue 915.2m / 840.1m) |
| TATA: -0.01 (NI 131.1m - CFO 136.5m) / TA 911.4m) |
| Beneish M = -1.69 (Cap -4..+1) = CCC |
As of July 11, 2026, the stock is trading at USD 51.76 with a total of 1,052,358 shares traded. Over the past week, the price has changed by +10.24%, over one month by +22.42%, over three months by -4.18% and over the past year by -62.83%.
Current recommended Stop Loss: 48.80 (which is 5.7% or 1.2 ATR below the current price).
Inspire Medical Systems has received a consensus analysts rating of 4.17. Therefore, it is recommended to buy INSP.
- StrongBuy: 8
- Buy: 5
- Hold: 5
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 51.8 | 0% |
P/E Trailing = 10.6705
P/E Forward = 104.1667
P/S = 1.478
P/B = 1.6531
Revenue TTM = 915.2m USD
EBIT TTM = 64.1m USD
EBITDA TTM = 80.1m USD
Long Term Debt = unknown (none)
Short Term Debt = 2.16m USD (from shortTermDebt, last fiscal year)
Debt = 29.6m USD (from shortLongTermDebtTotal, last quarter) (leases 29.6m already included)
Net Debt = -254.3m USD (calculated: Debt 29.6m - CCE 283.8m)
Enterprise Value = 1.10b USD (1.35b + Debt 29.6m - CCE 283.8m)
Interest Coverage Ratio = 467.7 (Ebit TTM 64.1m / Interest Expense TTM 137k)
EV/FCF = 11.36x (Enterprise Value 1.10b / FCF TTM 96.7m)
FCF Yield = 8.80% (FCF TTM 96.7m / Enterprise Value 1.10b)
FCF Margin = 10.57% (FCF TTM 96.7m / Revenue TTM 915.2m)
Net Margin = 14.33% (Net Income TTM 131.1m / Revenue TTM 915.2m)
Gross Margin = 85.78% ((Revenue TTM 915.2m - Cost of Revenue TTM 130.2m) / Revenue TTM)
Gross Margin QoQ = 86.47% (prev 86.59%)
Tobins Q-Ratio = 1.21 (Enterprise Value 1.10b / Total Assets 911.4m)
Interest Expense / Debt = 0.46% (Interest Expense 137k / Debt 29.6m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = 50.6m (EBIT 64.1m * (1 - 21.00%))
Current Ratio = 6.34 (Total Current Assets 566.8m / Total Current Liabilities 89.4m)
Debt / Equity = 0.04 (Debt 29.6m / totalStockholderEquity, last quarter 792.3m)
Debt / EBITDA = -3.17 (Net Debt -254.3m / EBITDA 80.1m)
Debt / FCF = -2.63 (Net Debt -254.3m / FCF TTM 96.7m)
Total Stockholder Equity = 729.4m (last 4 quarters mean from totalStockholderEquity)
RoA = 15.97% (Net Income 131.1m / Total Assets 911.4m)
RoE = 17.98% (Net Income TTM 131.1m / Total Stockholder Equity 729.4m)
RoCE = 7.80% (EBIT 64.1m / Capital Employed (Total Assets 911.4m - Current Liab 89.4m))
RoIC = 6.50% (NOPAT 50.6m / Invested Capital 778.4m)
WACC = 6.12% (E(1.35b)/V(1.38b) * Re(6.25%) + D(29.6m)/V(1.38b) * Rd(0.46%) * (1-Tc(0.21)))
Discount Rate = 6.25% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -46.67 | Cagr: -2.29%
[DCF] Terminal Value 77.97% ; FCFF base≈89.6m ; Y1≈102.7m ; Y5≈151.1m
[DCF] Fair Price = 87.74 (EV 2.27b - Net Debt -254.3m = Equity 2.53b / Shares 28.8m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 1.61 | # QB: 16
Revenue Correlation: 97.55 | Revenue CAGR: 22.73% | SUE: 2.36 | # QB: 3
EPS current Quarter (2026-06-30): EPS=-0.25 | Chg30d=+1.17% | Revisions=+0% | Analysts=13
EPS next Quarter (2026-09-30): EPS=0.14 | Chg30d=-15.59% | Revisions=-67% | Analysts=13
EPS current Year (2026-12-31): EPS=0.91 | Chg30d=+0.63% | Revisions=+25% | GrowthEPS=-62.6% | GrowthRev=-7.5%
EPS next Year (2027-12-31): EPS=1.28 | Chg30d=-1.83% | Revisions=-80% | GrowthEPS=+41.4% | GrowthRev=+3.9%
[Analyst] Revisions Ratio: -70% (up=3, down=24)